Clinical Viewpoint: Fallout from the IABP Shock II and Alt-Shock Studies

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>advisory board - Abiomed; Boston Scientific Corporation</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - Impluse Dynamics</li></ul>